For a quarter century, Drug Development & Delivery has connected innovators, scientists, and industry leaders while spotlighting the technologies and ideas shaping the future of the industry. We celebrate 25 years of advancing the conversation!
In this case study, OSDPredict™ narrowed formulation options early, focusing development on the most viable strategies which reduced experimental burden and conserved valuable materials.
As clinical trials become increasingly digitally enabled, organizations must look beyond successful technology deployment to determine whether new tools are delivering measurable value. This article presents a five-layer framework for evaluating technical fitness, workflow integration, adoption, data reliability, and operational outcomes to help translate clinical technology investments into better trial execution and evidence.
Ahead of CPHI, Cindy H. Dubin learns from leading excipient suppliers how multi-functional and organic excipients are impacting novel formulations and how AI is becoming a valuable tool in formulation development.
Dr. Shaukat Ali and Dr. Jim Huang shed light on the challenges and opportunities to improve solubility and enhance oral bioavailability of molecules in nanocrystals or crystalline suspensions.
Laxman Halleppanavar and David Phasey offer a focused perspective on connecting formulation, particle engineering, aseptic manufacturing, device design, and patient use within one scalable development pathway.
Kurt R. Sedo and Cindy H. Dubin take a deep dive into the excipient market, highlighting how new excipients enable advanced drug products and how AI and computation tools are helping match excipients to APIs.
Matthew Kihara explains how silicone lends itself to optimization, customization, and therapeutic performance, and that modifying silicone chemistry presents an opportunity to optimize drug release behavior and system performance.
Robin Cohen says that novel vaccine technology does not relate simply to the antigen, but also to method of administration and route of delivery, stressing that removing needle, syringe, and refrigerator are a step toward better vaccination programs.
Cindy H. Dubin speaks with injection device developers about creating devices that are intelligent, intuitive, patient-centric systems that make advanced therapies easier, safer, and more accessible to use at home.
ProMed Pharma is your distinguished development partner in long-acting injectable and implantable dosage forms. With nearly 20 years of operational history, we have honed our expertise in polymer-based dosage forms, achieving mastery in extended-release dosing. Our proficiency spans molding, extrusion, and microencapsulation techniques, leveraging a diverse spectrum of polymeric excipients encompassing silicones, thermoplastics, and biodegradables. At ProMed Pharma, our commitment to rapid project execution is underpinned by a steadfast dedication to scientific inquiry and technical finesse. Whether you represent an emerging biotech venture or a global pharmaceutical entity, entrust us as your CDMO partner, as we diligently translate scientific concepts into finished dosage forms.
As Part of Terumo Medical Care Solutions, the Pharmaceutical Solutions Division develops patient-oriented parenteral delivery solutions for therapeutic performance and safety.
Globally trusted for quality and precision, we offer pharmaceutical and medical device manufacturers around the world comprehensive product design and development services.
We have decades of experience collaborating with pharmaceutical companies from the earliest phases of drug development to product commercialization to optimize critical aspects of parenteral drug delivery.
Large-Scale LNP Process Conversions: The many hurdles of LNP scale-up and what to consider
Lipid nanoparticle (LNP) formulation development begins on a small scale, often with homemade or benchtop setups, using syringe pumps and easily accessible micro-mixing systems. Once …
Sustained release drug delivery is rapidly expanding across respiratory, ophthalmic, transdermal, and implantable applications, but translating products from development to manufacturing remains both complex and costly. Programs can stall due to material–drug compatibility issues, inconsistent release profiles, tooling-related variability, and …
A technology agnostic approach based on a fundamental understanding of API properties, a well-defined yet flexible target product profile, and a mindset for scalability and commercial relevance leads to success in formulation development and drug product design.
In this whitepaper, …
DRUG DEVELOPMENT DIRECT RESOURCES
Upcoming eNewsletter Features:
October 14 – Injection Devices
October 21 – Transdermal/Topical Delivery
October 28 – Formulation Development
November 4 – Drug Delivery